Early research (Phase 1)Ended earlyNCT02267863
What this trial is testing
APTO-253 in Patients With Relapsed or Refractory AML or MDS
Who this might be right for
Acute Myelogenous Leukemia in RelapseAcute Myelogenous Leukemia, Relapsed, AdultAcute Myelogenous Leukemia, Adult+2 more
Aptose Biosciences Inc. 21